A study of 3clpros as promising targets against sars-cov and sars-cov-2

Seri Jo, Suwon Kim, Jahyun Yoo, Mi Sun Kim, Dong Hae Shin

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


The outbreak of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), results in serious chaos all over the world. In addition to the available vaccines, the development of treatments to cure COVID-19 should be done quickly. One of the fastest strategies is to use a drug-repurposing approach. To provide COVID-19 patients with useful information about medicines currently being used in clinical trials, twenty-four com-pounds, including antiviral agents, were selected and assayed. These compounds were applied to verify the inhibitory activity for the protein function of 3CLpros (main proteases) of SARS-CoV and SARS-CoV-2. Among them, viral reverse-transcriptase inhibitors abacavir and tenofovir revealed a good inhibitory effect on both 3CLpros. Intriguingly, sildenafil, a cGMP-specific phosphodiesterase type 5 inhibitor also showed significant inhibitory function against them. The in silico docking study suggests that the active-site residues located in the S1 and S2 sites play key roles in the interactions with the inhibitors. The result indicates that 3CLpros are promising targets to cope with SAR-CoV-2 and its variants. The information can be helpful to design treatments to cure patients with COVID-19.

Original languageEnglish
Article number756
Issue number4
StatePublished - Apr 2021


  • Antiviral
  • Drug repurposing
  • FRET
  • Inhibitory compounds
  • SARS-CoV-2 3CL protease


Dive into the research topics of 'A study of 3clpros as promising targets against sars-cov and sars-cov-2'. Together they form a unique fingerprint.

Cite this